- /
- Supported exchanges
- / US
- / SLNO.NASDAQ
Soleno Therapeutics Inc (SLNO NASDAQ) stock market data APIs
Soleno Therapeutics Inc Financial Data Overview
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Soleno Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Soleno Therapeutics Inc data using free add-ons & libraries
Get Soleno Therapeutics Inc Fundamental Data
Soleno Therapeutics Inc Fundamental data includes:
- Net Revenue: 190 M
- EBITDA: 16 967 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-11
- EPS/Forecast: 0.215
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Soleno Therapeutics Inc News
New
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Soleno Therapeutics, Inc., Announces Opportunity for Investors with Substantial Losses to Lead Soleno Class Action Lawsuit
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November ...
Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most shorted stocks to buy according to analysts. On February 25, Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for th...
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here’s Why
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best cheap biotech stocks to buy now. Wells Fargo cut the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $110 from $114 on February 27...
Soleno Profitability Milestone And CFO Shift Raise Valuation Questions
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Soleno Therapeutics (NasdaqCM:SLNO) reports achieving full year profitability within nine m...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.